ADR-002K
/ Rohto Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 26, 2025
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: Rohto Pharmaceutical Co., Ltd.
New P2 trial • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure
1 to 1
Of
1
Go to page
1